| Literature DB >> 2564505 |
F Crea1, G Pupita, A R Galassi, H el Tamimi, J C Kaski, G J Davies, A Maseri.
Abstract
In a single-blind, placebo-controlled, randomised trial in 20 patients with stable angina pectoris, intravenous theophylline ethylenediamine (aminophylline), 7 mg/kg, increased the time to onset of angina by 46%, the heart-rate/blood-pressure product (an index of myocardial oxygen consumption) at 1 mm ST segment depression by 22%, and exercise duration by 24%. In a subsequent double-blind placebo-controlled trial in 8 patients a single oral dose of theophylline (375 mg) increased the time to onset of angina by 56%, the heart-rate/blood-pressure product at 1 mm ST segment depression by 22%, and the exercise duration by 35%. Infusion of theophylline ethylenediamine during angiography (10 patients) did not affect the diameter of epicardial coronary arteries. The beneficial effects of theophylline may be due to redistribution of coronary blood flow from non-ischaemic to ischaemic myocardium.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2564505 DOI： 10.1016/s0140-6736(89)92204-6
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321